

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2915548

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
UCB BIOPHARMA, S.A.	06/23/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	UCB BIOPHARMA SPRL
<b>Street Address:</b>	60, ALLÉE DE LA RECHERCHE
<b>City:</b>	BRUSSELS
<b>State/Country:</b>	BELGIUM
<b>Postal Code:</b>	B-1070
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14309118
<b>Application Number:</b>	13656922
<b>Application Number:</b>	12532517
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(352)372-5800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	3523758100
<b>Email:</b>	fce@slepatents.com
<b>Correspondent Name:</b>	FRANK C. EISENSCHENK, PH.D.
<b>Address Line 1:</b>	P.O. BOX 142950
<b>Address Line 4:</b>	GAINESVILLE, FLORIDA 32614-2950
<b>NAME OF SUBMITTER:</b>	FRANK C. EISENSCHENK, PH.D.
<b>SIGNATURE:</b>	/FRANK C. EISENSCHENK/
<b>DATE SIGNED:</b>	06/26/2014
<b>Total Attachments: 1</b>	
source=executedAsgn-Phamra2Biop#page1.tif	

ASSIGNMENT FROM UCB PHARMA S.A.  
TO  
UCB BIOPHARMA SPRL

In consideration of one dollar (\$1.00) and other good and valuable consideration, UCB PHARMA, S.A., having a place of business at 60, Allée de la Recherche, B-1070 Brussels, Belgium, sells and assigns to UCB BIOPHARMA SPRL, having a place of business at 60, Allée de la Recherche, B-1070 Brussels, Belgium, its successors and assigns, UCB PHARMA S.A.'s entire right, title and interest throughout the world in and to the improvements in:

"Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof"; U.S. Patent Application Serial No. 12/532,517, filed September 22, 2009, now U.S. Patent No. 8,293,237, issued on October 23, 2012; and

"Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof"; U.S. Patent Application Serial No. 13/656,922, filed October 22, 2012;

and in and to said application and all patents (foreign and domestic) which may be granted therefor and thereon, and all divisions, reissues, continuations and extensions thereof (foreign and domestic), and UCB PHARMA S.A. authorizes and requests the Commissioner of Patents and Trademarks to issue all patents on said improvements or resulting therefrom to said UCB BIOPHARMA SPRL, as assignee of the entire interest; and it agrees that it will sign all lawful papers, execute all divisional, continuing and reissue applications, and make all rightful oaths to aid said UCB BIOPHARMA SPRL, its successors, assigns and nominees, to obtain and enforce proper protection for said improvements in all countries.

Executed this \_\_\_\_ day of 23 JUN 2014, 2014.

UCB BIOPHARMA, S.A.

By: \_\_\_\_\_

Printed Name:

Title:

  
**Stéphane DROUIN**  
Proxy and Legal Representative

WITNESS:

Signature: \_\_\_\_\_

Printed Name: Marina CRAINICH

Date: 23/06/2014

Page 1 of 1